Observational Study to Evaluate Hematopoietic Progenitor Cell Mobilization in Patients With Newly Diagnosed Multiple Myeloma

High dose therapy (HDT) and autologous hematopoietic cell transplantation (autoHCT) is
considered standard therapy for younger, transplant eligible multiple myeloma (MM) patients.
Mobilization of peripheral blood progenitor cells (PBPC) for HDT and autoHCT can be
accomplished by using cytokines, most commonly granulocyte-colony stimulating factor (G-CSF),
either alone or in combination with chemotherapy or plerixafor.

Limitations of cytokine-only mobilization in myeloma:

There is little consensus about the optimal method for PBPC mobilization in patients with MM,
although there is a growing recognition of suboptimal mobilization outcomes of certain
subgroups of myeloma patients mobilized with G-CSF alone. Within this context, the adverse
impact of prior lenalidomide therapy on PBPC mobilization is well documented; with up to 40%
of MM patients treated with lenalidomide-based induction chemotherapies not collecting ≥2 x
106 CD34+ cells/kg when mobilized with G-CSF alone.

Chemomobilization in myeloma:

In contrast, mobilization with chemotherapy (mostly cyclophosphamide) in addition to G-CSF
has been shown to improve PBPC collection yield and reduce mobilization failure rates in
comparison to G-CSF alone. Limited retrospective data suggest that cyclophosphamide may
overcome the effects of prior lenalidomide exposure on PBPC mobilization in MM patients.
Cyclophosphamide doses employed for mobilization of PBPC in MM patients in most reports have
ranged from 1 gm/m2 up to 7 gm/m2. Several studies have assessed the relative impact of
cyclophosphamide dose-intensity on PBPC mobilization in myeloma patients treated with
conventional chemotherapy regimens. In general PBPC mobilization with high-dose
cyclophosphamide (HD-CY) (7 gm/m2) plus G-CSF was found to be significantly more toxic, when
compared to intermediate-dose cyclophosphamide (ID-CY) (3-4 gm/m2) and G-CSF, without any
convincing evidence of superior efficacy. Studies comparing mobilization with ID-CY plus
G-CSF with low-dose cyclophosphamide (LD-CY) (1-2 gm/m2) plus G-CSF, reported higher total
CD34+ cell yield with ID-CY, but at the cost of higher toxicity. However, no significant
difference in mobilization failure rates between the ID- and LD-CY mobilization has been
reported. But these data might not be applicable to MM treated in the era of novel agents.
Hamadani et al. compared the efficacy and toxicity of PBPC mobilization with G-CSF and either
ID-CY or LD-CY, in MM patients receiving only novel induction regimens, and reported a more
robust PBPC mobilization and significantly reduced the rates of mobilization failure with
ID-CY in MM patients receiving modern inductions. Within the context of stem cell
mobilization in MM patients treated with novel inductions, it appears that ID-CY and G-CSF
may have a favorable risk/benefit ratio and can be considered a regimen with an optimal
dose-intensity in order to assess the efficacy of novel mobilization regimens against
cyclophosphamide-based mobilizing strategies. But these single center observations merit
confirmation in large, multicenter datasets.

Plerixafor-based mobilization in myeloma:

Plerixafor is a small molecule that inhibits chemokine stromal cell derived factor 1-alpha
from binding to CXC chemokine receptor 4, resulting in increased hematopoietic stem and
progenitor cell migration into peripheral blood circulation. Plerixafor use in combination
with G-CSF has resulted in significant improvements in the mobilization outcomes of MM
patients. Despite the promising results of plerixafor and G-CSF for PBPC mobilization, the
use of chemotherapy-based mobilization regimens remain standard practice in many transplant
centers, driven in part due the costs associated with plerixafor based strategies.

Chemomobilization vs. Plerixafor-based mobilization in myeloma:

No randomized trials comparing chemomobilization vs. plerixafor plus G-CSF in patients with
myeloma have been published. While a few retrospective studies have reported on the relative
efficacy of cyclophosphamide-based mobilization against plerixafor and G-CSF, they included
patients receiving either LD-CY or doses above 4mg/m2, contained patients with non-Hodgkin
lymphoma (NHL), and likely included MM patients receiving conventional induction regimens.
Awan et al. retrospectively compared that efficacy, toxicity and cost of PBPC mobilization
with G-CSF and either ID-CY or plerixafor, in MM patients receiving only novel induction
regimens. Compared to plerixafor, ID-CY use was associated with higher median peak peripheral
blood CD34+ cell count (68/µL vs. 160/µL, p<0.001), and CD34+ cell yield on day 1 of
collection (6.9 x 106/kg vs. 11.7 x 106/kg, p=<0.001). No patients in either group had
mobilization failure. The total CD34+ cell yield was significantly higher in the ID-CY
patients (median collection 16.6 x 106 cells/kg vs. 11.6 x 106 cells/kg; p-value <0.001).
Mobilization with ID-CY was associated with significantly more frequent episodes of febrile
neutropenia (16.3% vs. 0%; p=0.02), higher use of intravenous antibiotics (16.3% vs. 3%;
p=0.03), transfusion support and need for hospitalizations (p=0.02). The average total cost
of mobilization in the plerixafor group was significantly higher compared to the ID-CY group
($28,980 vs. $22,504.8; p-value=0.001). This study showed lower mobilization costs but
greater toxicity with chemotherapy based mobilization in MM. The limitations of the analysis
include small sample size and retrospective nature. Of note LD-CY in a different study was
shown to be inferior to plerixafor in terms of PBPC mobilization efficacy and collection
failure rates.

As needed or Just-in-time Plerixafor:

As noted previously, plerixafor combined with G-CSF provides superior mobilization outcomes
in MM and NHL compared to G-CSF alone. It has also been shown to be an effective salvage
option for patients failing to collect adequate CD34+ cells with G-CSF alone or
chemomobilization [24-26]. However, the high cost of plerixafor has limited its routine use
in HPC mobilization. Risk-adapted algorithms have been developed in several institutions to
rescue patients at high-risk for mobilization failure and restrict plerixafor use to curtail
mobilization costs. Veltri et al. recently reported a single institution comparative analysis
of patients with MM and lymphoma who underwent G-CSF mobilization, with plerixafor used
either routinely or as needed in patients at risk for mobilization failure. This analysis
showed no mobilization failure events with either administering plerixafor routinely to all
patients vs. by using a JIT approach, but showed that JIT method was associated with
significantly lower collection costs.

While it is clear that PBPC mobilization has been a subject of several reports, including a
recent registry analysis, these reports are limited by their retrospective nature, small
sample size, heterogeneity of patient population and often missing information on healthcare
resource utilization. In the current large, multicenter, observational study the
investigators intend to collect detailed information regarding patient, disease, mobilization
and healthcare utilization characteristic in a prospective fashion. This prospective,
mobilization, registry dataset would then be used to evaluate efficacy of various
mobilization regimens, their cost, associated healthcare resource utilization and impact on
post transplantation outcomes.

Inclusion Criteria:

- Myeloma patients ages 18-70 years.

- Undergoing upfront autoHCT (≤12 months from start of initial therapy for myeloma).

Exclusion Criteria:

- Patients with light chain (AL) amyloidosis or myeloma with associated AL amyloidosis.

- POEMS syndrome